These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 25940651)

  • 1. Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
    Werth S; Breslin T; NiAinle F; Beyer-Westendorf J
    Am J Cardiovasc Drugs; 2015 Aug; 15(4):235-42. PubMed ID: 25940651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monitoring options and reversal agents for oral anticoagulants].
    Thorup SB; Husted SE; Vang ML
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
    Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
    Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
    Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
    Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician.
    Thachil J; Gagg J
    Acute Med; 2015; 14(2):83-9. PubMed ID: 26305087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Bleeding Associated with New Oral Anticoagulants.
    Franchini M; Bonfanti C; Mannucci PM
    Semin Thromb Hemost; 2015 Oct; 41(7):788-801. PubMed ID: 26408923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
    Darius H
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?].
    Buerke M; Hoffmeister HM
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):105-110. PubMed ID: 28074293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory monitoring of the non-vitamin K oral anticoagulants.
    Blann AD; Lip GY
    J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
    [No Abstract]   [Full Text] [Related]  

  • 17. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gastrointestinal bleeding during treatment with non­vitamin K antagonist oral anticoagulants (NOACs) may be caused by malignant lesions].
    Haeggström A; Risberg D; Al-Kahlili F; Gilstring Å; Tullberg U; Wallén H
    Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Plitt A; Ruff CT; Giugliano RP
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1019-34. PubMed ID: 27637305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.